{"id":"W2624483458","doi":"10.1200/jco.2017.35.15_suppl.1008","title":"Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Internal medicine; Breast cancer; Metastatic breast cancer; Oncology; Cancer; Tolerability; Adverse effect; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003913015,0.0002755679,0.002946325,0.0001774599,0.0001748985,0.00002700569,0.0004510808,0.0002632957,0.0003295922],"category_scores_gemma":[0.001790809,0.0001848153,0.001004965,0.0001197378,0.0004718766,0.0002175461,0.00003527482,0.0006012539,0.000001789158],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002967937,"about_ca_system_score_gemma":0.002097012,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009008944,"about_ca_topic_score_gemma":0.0004719401,"domain_scores_codex":[0.994874,0.0005717153,0.003418218,0.0003272396,0.0004660314,0.0003427962],"domain_scores_gemma":[0.9903578,0.001812984,0.005867176,0.0005686745,0.001073305,0.0003200373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.4041972,0.02373864,0.1055766,0.0001083988,0.009945001,0.0002642788,0.0008478347,0.000007882505,0.001473261,0.000007371563,0.004607892,0.4492257],"study_design_scores_gemma":[0.3244186,0.1056767,0.5544802,0.000302491,0.003775705,0.0004169528,0.0005950746,0.0002613241,0.000735929,0.0001328879,0.008963955,0.0002401198],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914324,0.0007748693,0.0001909932,0.003714064,0.001225965,0.002238118,0.00008635658,0.00001071176,0.0003265627],"genre_scores_gemma":[0.9938853,0.002675261,0.0009182476,0.0008914674,0.0007789584,0.00009624725,0.000003822018,0.00004167169,0.0007090392],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4489856,"threshold_uncertainty_score":0.753655,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1507263643277155,"score_gpt":0.524890833082499,"score_spread":0.3741644687547835,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}